AnGes Inc banner

AnGes Inc
TSE:4563

Watchlist Manager
AnGes Inc Logo
AnGes Inc
TSE:4563
Watchlist
Price: 61 JPY 1.67% Market Closed
Market Cap: ¥24.1B

AnGes Inc
Investor Relations

AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 131 full-time employees. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Ei Yamada M.D., Ph.D.
CEO, President & Representative Director
No Bio Available
Mr. Naoya Sato
Director of Corporate Development & Director
No Bio Available

Contacts

Address
OSAKA-FU
Ibaraki-shi
1F, Saito Bio-Incubator, 7-7-15, Saito-Asagi
Contacts
+81357302641.0
www.anges.co.jp